CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (NCT05931276)
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)
🩺 Plain-English Summary (8th-Grade Level)
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Who can join: Review the eligibility criteria below.
Location: VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
- North Florida/South Georgia Veterans Health System, Gainesville, FL — Gainesville, Florida
- Atlanta VA Medical and Rehab Center, Decatur, GA — Decatur, Georgia
- Iowa City VA Health Care System, Iowa City, IA — Iowa City, Iowa
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA — Boston, Massachusetts
- Minneapolis VA Health Care System, Minneapolis, MN — Minneapolis, Minnesota
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE — Omaha, Nebraska
- New Mexico VA Health Care System, Albuquerque, NM — Albuquerque, New Mexico
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in End-Stage Kidney Disease
- The Arteriovenous Vascular (AV) ACCESS Trial — Birmingham, Alabama
- Symptom Management in Patients on Dialysis — Brampton, Ontario
- Incremental Hemodialysis: The TwoPlus Trial — Jacksonville, Florida
- Randomised Evaluation of Sodium Dialysate Levels on Vascular Events — Adelaide,
Explore by condition: All End-Stage Kidney Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.